Literature DB >> 12692541

Human susceptibility and resistance to Norwalk virus infection.

Lisa Lindesmith1, Christine Moe, Severine Marionneau, Nathalie Ruvoen, Xi Jiang, Lauren Lindblad, Paul Stewart, Jacques LePendu, Ralph Baric.   

Abstract

Infectious diseases have influenced population genetics and the evolution of the structure of the human genome in part by selecting for host susceptibility alleles that modify pathogenesis. Norovirus infection is associated with approximately 90% of epidemic non-bacterial acute gastroenteritis worldwide. Here, we show that resistance to Norwalk virus infection is multifactorial. Using a human challenge model, we showed that 29% of our study population was homozygous recessive for the alpha(1,2)fucosyltransferase gene (FUT2) in the ABH histo-blood group family and did not express the H type-1 oligosaccharide ligand required for Norwalk virus binding. The FUT2 susceptibility allele was fully penetrant against Norwalk virus infection as none of these individuals developed an infection after challenge, regardless of dose. Of the susceptible population that encoded a functional FUT2 gene, a portion was resistant to infection, suggesting that a memory immune response or some other unidentified factor also affords protection from Norwalk virus infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692541     DOI: 10.1038/nm860

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  417 in total

1.  Increased susceptibility of secretor factor gene Fut2-null mice to experimental vaginal candidiasis.

Authors:  Elizabeth A Hurd; Steven E Domino
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

2.  Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane.

Authors:  Masaru Tamura; Katsuro Natori; Masahiko Kobayashi; Tatsuo Miyamura; Naokazu Takeda
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype.

Authors:  Philipp Rausch; Ateequr Rehman; Sven Künzel; Robert Häsler; Stephan J Ott; Stefan Schreiber; Philip Rosenstiel; Andre Franke; John F Baines
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-08       Impact factor: 11.205

Review 4.  Update in asthma 2011.

Authors:  Shamsah Kazani; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

5.  Development of a latex agglutination test for norovirus detection.

Authors:  Heetae Lee; YoungBin Park; Misoon Kim; Youngmee Jee; Doo-Sung Cheon; Hae Sook Jeong; GwangPyo Ko
Journal:  J Microbiol       Date:  2010-08-20       Impact factor: 3.422

6.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  The carbohydrate moiety and high molecular weight carrier of histo-blood group antigens are both required for norovirus-receptor recognition.

Authors:  Pengwei Huang; Ardythe L Morrow; Xi Jiang
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

8.  Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children.

Authors:  Nguyen Van Trang; Hau ThiBich Vu; Nhung ThiHong Le; Pengwei Huang; Xi Jiang; Dang Duc Anh
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

Review 9.  The challenge and promise of glycomics.

Authors:  Richard D Cummings; J Michael Pierce
Journal:  Chem Biol       Date:  2014-01-16

10.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.